Ranchi News Desk

Real World Evidence Solutions Market to Reach USD 2.9 Billion Globally by 2027 at 15.2% CAGR – Exclusive Report by MarketsandMarkets™

 Breaking News
  • No posts were found

Real World Evidence Solutions Market to Reach USD 2.9 Billion Globally by 2027 at 15.2% CAGR – Exclusive Report by MarketsandMarkets™

November 17
18:32 2022
Real World Evidence Solutions Market to Reach USD 2.9 Billion Globally by 2027 at 15.2% CAGR - Exclusive Report by MarketsandMarkets™
The key players operating in the RWE solutions market include IQVIA Holdings Inc. (US), IBM Corporation (US), OPTUM Inc. (US), Icon Plc (Ireland), Syneos Health Inc. (US), Parexel International Corporation (US)
In August 2022, Trinity Life Sciences (US), announced a partnership with Bain & Company (US). The partnership is intended to pair the extensive experience of Bain & Company (US) in the Life Sciences value chain with the evidence-based solutions of Trinity Life Sciences (US).

Real World Evidence Solutions Market size is projected to reach USD 2.9 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 15.2% during the forecast period according to a new report by MarketsandMarkets™. Potential of RWE in reducing drug development costs and expediting the drug development process, shift from volume- to value-based care, rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases, and increased R&D spending for the development of new pharmaceutical products and medical devices are driving the growth of RWE solutions market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

Browse in-depth TOC on “Real World Evidence Solutions Market”

190 – Tables

60 – Figures

265 – Pages

By component, services is expected to witness the fastest growth during the forecast period

Based on component, the RWE solutions market is segmented into data sets and services. In 2021, the services segment accounted for a larger share in the global RWE solutions market. Vendors in the RWE solutions market offers advanced analytics services and consulting services. Increasing demand for converting the data into actionable evidence is increasing the need to reduce drug development delays utilizing specific RWE services. The data sets are further segmented into disparate data sets and integrated data sets. The disparate data sets dominates by types of data sets in 2021. The growing adoption of digital healthcare trends has contributed to the increased availability of disparate data sources, such as EHR and patient/disease registries. Additionally, owing to the increasing use of these data sets in monitoring the safety of health products, regulatory authorities are taking initiatives to promote the better use of available data sets, which is driving the market growth for disparate data sets. The disparate data sets are further subsegmented into clinical settings data, claims data, pharmacy data, patient-powered data, and other data sets. In 2021, clinical settings data accounted for a dominating share owing to the rising demand for de-identified patient data for research purposes.

Post-market surveillance and clinical & regulatory decision making segments are expected to show fastest growth during the forecast period.

Based on application, the RWE solutions market is segmented into drug development and approvals, medical device development and approvals, post-market surveillance, market access reimbursement/coverage decision making, and clinical and regulatory decision-making. The post-market surveillance and clinical & regulatory decision making segments are expected to show the fastest growth rate during the forecast period owing to the increased incidence of adverse events, rise in concerns for patient safety, and growing importance of RWE in regulatory decision makings.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991

Pharmaceutical & medical device companies is expected to remain the dominating  segment in 202

Based on end user, the RWE solutions market is segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users. The pharmaceutical & medical device companies segment dominates the end user segment and is also expected to witness highest growth rate during the forecast period. The large share and high growth of this end-user segment can be attributed to the need to prevent costly drug recalls and increasing importance of RWE studies in drug approvals. RWE data  is needed  for new drugs to sucessfuly pass-through clinical phases. Hence, the successful phase transition of any drugs across pharmaceutical company depends on the strong real-world outcomes.

Asia Pacific to witness the highest growth rate during the forecast period

By Region, the RWE solutions market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to show the highest growth rate during the forecast period. Increasing government initiatives for the adoption of RWE studies, rising geriatric population, and rising number of clinical trials are driving the growth of RWE solutions market in Asia Pacific region.

The key players operating in the RWE solutions market include IQVIA Holdings Inc. (US), IBM Corporation (US), OPTUM Inc. (US), Icon Plc (Ireland), Syneos Health Inc. (US), Parexel International Corporation (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=76173991

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/real-world-evidence-solution-market-76173991.html

Related Articles